Recently, Esser et al. evaluated responses of PDO to immunotherapy through investigating necrosis area and area of viable cells in H&E stained slides.21 In patients with ccRCC, Krishna et al. also reported that elevated level of CD8+CD69+ T cells after PD-1 blockade can be observed in responsive patients.11 In this research, we applied the ratio of CD8+ T cell subset among total CD3+ T cells, CD69+ T cell subset among total CD8+ T cells, and cell viability staining to evaluate the response to immunotherapy. This evidence concerns the gene CD69 and nonpapillary renal cell carcinoma.